<?xml version="1.0" encoding="UTF-8"?>
<p class="p">The inhibitory activities of xanthophyll carotenoids have been demonstrated for inducible NOS or COX-2 enzymes in cell lines (e.g., BV2 microglial cells and RAW 264.7 macrophage cells) that were stimulated by LPS [
 <xref rid="B247-marinedrugs-17-00304" ref-type="bibr" class="xref">247</xref>,
 <xref rid="B248-marinedrugs-17-00304" ref-type="bibr" class="xref">248</xref>]. Astaxanthin has been reported to inhibit the production of nitrous oxide (NO), prostaglandin E2 (PGL2), and to lower the levels of proinflammatory cytokines, TNF-α, IL-1β, and IL-6 [
 <xref rid="B247-marinedrugs-17-00304" ref-type="bibr" class="xref">247</xref>,
 <xref rid="B249-marinedrugs-17-00304" ref-type="bibr" class="xref">249</xref>]. In addition, treatment with astaxanthin at 5 mM was found to improve the phagocytic and microbicide function, and to reduce the oxidative damage to lipids and proteins in human neutrophils [
 <xref rid="B250-marinedrugs-17-00304" ref-type="bibr" class="xref">250</xref>]. Furthermore, cells pre-incubated with astaxanthin restored expression levels of SHP-1, a small heterodimer protein tyrosine phosphatase, and reduced the expression of NF-κB [
 <xref rid="B249-marinedrugs-17-00304" ref-type="bibr" class="xref">249</xref>].
</p>
